All In Biotech

NDA 022046 · Hospira

Bupivacaine Hydrochloride

Bupivacaine Hydrochloride, Epinephrine Bitartrate · Injection

Last checked: Nov 20, 2026Latest source record: Nov 2, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1983

Jul 13, 1983

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,836

341 Phase 3, 228 recruiting

FAERS reports

2,117

1,388 serious, 225 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 13, 1983 Original approval
2 products under this application
  • BUPIVACAINE HYDROCHLORIDE · BUPIVACAINE HYDROCHLORIDE 0.5% · INJECTABLE, INJECTION · Prescription
  • BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE · BUPIVACAINE HYDROCHLORIDE 0.5%; EPINEPHRINE BITARTRATE 0.0091MG/ML · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Bupivacaine" as an intervention, any sponsor and status, largest first.

All 2,836 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective581
  • maternal exposure during pregnancy197
  • anaesthetic complication196
  • off label use165
  • hypoaesthesia144
  • hypotension125
  • condition aggravated123
  • dyspnoea117
  • hypertension117
  • headache112
  • fatigue99
  • dizziness94

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20053
200613
20077
20089
200924
201032
201110
201221
201326
201421
201594
2016280
201732
201865
201969
202094
2021135
2022241
2023182
2024270
2025282
2026207

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5,896 on PubMed

Sponsor: Pfizer · Also marketed as Bupivacaine Hydrochloride and Epinephrine

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.